Cardiff Oncology Inc.
| NASDAQ: CRDF | Healthcare / Biotechnology / USA |
| 1.18 | -0.1000 | -7.81% | Vol 619.53K | 1Y Perf -22.89% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 1.18 | ASK | 1.24 | ||
| Open | 1.26 | Previous Close | 1.28 | ||
| Pre-Market | - | After-Market | 1.19 | ||
| - - | 0.01 0.85% |
| Target Price | 8.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 577.97 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★★★★+ 58.61 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★★★+ 54.89 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | -1.26 | Earnings Rating | — | |
| Market Cap | 52.72M | Earnings Date | 2nd Nov 2023 | |
| Alpha | 0.01 | Standard Deviation | 0.32 | |
| Beta | 1.74 |
Today's Price Range 1.181.26 | 52W Range 1.202.79 | 5 Year PE Ratio Range -4.10-0.6000 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -20.00% | ||
| 1 Month | -30.81% | ||
| 3 Months | -7.25% | ||
| 6 Months | -16.34% | ||
| 1 Year | -22.89% | ||
| 3 Years | -90.30% | ||
| 5 Years | -73.66% | ||
| 10 Years | -99.76% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -29.13 | |||
ROE last 12 Months | -34.88 | |||
ROA (5Y Avg) | -10.06 | |||
ROA last 12 Months | -32.44 | |||
ROC (5Y Avg) | -120.81 | |||
ROC last 12 Months | -31.95 | |||
Return on invested Capital Q | -7.54 | |||
Return on invested Capital Y | -6.74 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.50 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.60 | ||||
| 0.57 | ||||
| 256.29 | ||||
| - | ||||
| -2.60 | ||||
| -0.75 | ||||
| 0.57 | ||||
| 2.53 | ||||
| -46 673 100.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 13.90 | ||||
| 14.50 | ||||
| 0.02 | ||||
| 0.03 | ||||
| -17 679.10 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -10 095.10 | ||||
| -10 027.90 | ||||
| -5 672.70 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 258.00K | ||||
| 0.01 | ||||
| -7.04 | ||||
| -2.84 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.27 | -0.25 | 7.41 |
| Q01 2023 | -0.23 | -0.25 | -8.70 |
| Q04 2022 | -0.25 | -0.20 | 20.00 |
| Q03 2022 | -0.27 | -0.20 | 25.93 |
| Q02 2022 | -0.25 | -0.24 | 4.00 |
| Q01 2022 | -0.23 | -0.25 | -8.70 |
| Q04 2021 | -0.17 | -0.23 | -35.29 |
| Q03 2021 | -0.17 | -0.17 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 2nd Nov 2023 |
| Estimated EPS Next Report | -0.29 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 619.53K |
| Shares Outstanding | 44.68K |
| Shares Float | 39.45M |
| Trades Count | 2.41K |
| Dollar Volume | 767.55K |
| Avg. Volume | 2.63M |
| Avg. Weekly Volume | 5.47M |
| Avg. Monthly Volume | 1.44M |
| Avg. Quarterly Volume | 977.91K |
Cardiff Oncology Inc. (NASDAQ: CRDF) stock closed at 1.28 per share at the end of the most recent trading day (a -1.54% change compared to the prior day closing price) with a volume of 633.27K shares and market capitalization of 52.72M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cardiff Oncology Inc. CEO is Mark Erlander.
The one-year performance of Cardiff Oncology Inc. stock is -22.89%, while year-to-date (YTD) performance is -8.57%. CRDF stock has a five-year performance of -73.66%. Its 52-week range is between 1.2 and 2.79, which gives CRDF stock a 52-week price range ratio of -1.26%
Cardiff Oncology Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 0.57, a price-to-sale (PS) ratio of 256.29, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -32.44%, a ROC of -31.95% and a ROE of -34.88%. The company’s profit margin is -%, its EBITDA margin is -10 027.90%, and its revenue ttm is $258.00 Thousand , which makes it $0.01 revenue per share.
Of the last four earnings reports from Cardiff Oncology Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. Cardiff Oncology Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Cardiff Oncology Inc. is Strong Buy (1), with a target price of $8, which is +577.97% compared to the current price. The earnings rating for Cardiff Oncology Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cardiff Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cardiff Oncology Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.48, ATR14 : 0.14, CCI20 : -186.97, Chaikin Money Flow : -0.62, MACD : -0.11, Money Flow Index : 81.99, ROC : -26.01, RSI : 27.19, STOCH (14,3) : 9.94, STOCH RSI : 0.00, UO : 33.21, Williams %R : -90.06), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cardiff Oncology Inc. in the last 12-months were: Mark Erlander (Buy at a value of $28 600)
Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
CEO: Mark Erlander
Telephone: +1 858 952-7570
Address: 11055 Flintkote Avenue, San Diego 92121, CA, US
Number of employees: 12
TipRanks News for CRDF
Wed, 27 Sep 2023 13:10 GMT Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Cardiff Oncology (CRDF) and Streamline Health Solutions (STRM)
- TipRanks. All rights reserved.
